name: Narcolepsy
category: Neurological
parents:
- Sleep Disorder
- Neurological Disease
disease_term:
  preferred_term: narcolepsy
  term:
    id: MONDO:0021107
    label: narcolepsy
has_subtypes:
- name: Narcolepsy Type 1
  description: With cataplexy and orexin/hypocretin deficiency.
- name: Narcolepsy Type 2
  description: Without cataplexy, normal or near-normal orexin levels.
pathophysiology:
- name: Orexin/Hypocretin Deficiency
  description: >
    Loss of orexin-producing neurons in the lateral hypothalamus leads to
    instability of sleep-wake states. Orexin normally promotes and stabilizes
    wakefulness. In Type 1 narcolepsy, >90% of orexin neurons are destroyed,
    likely through autoimmune mechanisms.
  cell_types:
  - preferred_term: Orexin Neuron
    term:
      id: CL:0011109
      label: hypocretin-secreting neuron
  biological_processes:
  - preferred_term: Sleep-Wake Regulation
    term:
      id: GO:0042745
      label: circadian sleep/wake cycle
  evidence:
  - reference: PMID:25728441
    supports: SUPPORT
    snippet: "Narcolepsy with cataplexy is caused by hypocretin deficiency owing to destruction of most of the hypocretin-producing neurons in the hypothalamus."
    explanation: Landmark review establishes hypocretin neuron loss as the cause of narcolepsy with cataplexy.
- name: Autoimmune Destruction
  description: >
    Strong HLA-DQB1*06:02 association suggests autoimmune etiology. T-cell
    mediated destruction of hypocretin neurons is the leading hypothesis.
    Environmental triggers (infections, H1N1 vaccination) may initiate
    the autoimmune response in genetically susceptible individuals.
  biological_processes:
  - preferred_term: Autoimmune Response
    term:
      id: GO:0002460
      label: adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
  evidence:
  - reference: PMID:25728441
    supports: SUPPORT
    snippet: "The hypothesis that a targeted immune-mediated or autoimmune attack causes the specific degeneration of hypocretin neurons arose mainly through the discovery of genetic associations, first with the HLA-DQB1*06:02 allele and then with the T-cell receptor Î± locus."
    explanation: Genetic associations with HLA and TCR loci strongly support autoimmune etiology.
  - reference: PMID:32227223
    supports: SUPPORT
    snippet: "Narcolepsy type 1 is hypothesized to be an autoimmune disease targeting the hypocretin/orexin neurons in the hypothalamus. Ample genetic and epidemiological evidence points in the direction of a pathogenesis involving the immune system"
    explanation: Recent review summarizing that genetic and epidemiological evidence supports autoimmune pathogenesis.
  - reference: PMID:38077397
    supports: SUPPORT
    snippet: "NT1 is a rare, life-long sleep disorder arising as a consequence of the extensive destruction of orexin-producing hypothalamic neurons. The mechanisms involved in the destruction of orexin neurons are not yet elucidated but the association of narcolepsy with environmental triggers and genetic susceptibility (strong association with the HLA, TCRs and other immunologically-relevant loci) implicates an immuno-pathological process."
    explanation: Transcriptomic study confirms the immunological basis and T-cell involvement in narcolepsy pathogenesis.
phenotypes:
- name: Excessive Daytime Sleepiness
  category: Sleep
  frequency: OBLIGATE
  diagnostic: true
  notes: Cardinal symptom, irresistible sleep attacks
  evidence:
  - reference: PMID:38077397
    supports: SUPPORT
    snippet: "NT1 is a rare, life-long sleep disorder arising as a consequence of the extensive destruction of orexin-producing hypothalamic neurons."
    explanation: Excessive daytime sleepiness results from loss of orexin neurons that regulate wakefulness.
  phenotype_term:
    preferred_term: Excessive Daytime Sleepiness
    term:
      id: HP:0002329
      label: Drowsiness
- name: Cataplexy
  category: Motor
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Sudden muscle weakness triggered by emotions, pathognomonic for Type 1
  evidence:
  - reference: PMID:25728441
    supports: SUPPORT
    snippet: "Narcolepsy with cataplexy is caused by hypocretin deficiency owing to destruction of most of the hypocretin-producing neurons in the hypothalamus."
    explanation: Cataplexy is the defining feature that distinguishes Type 1 narcolepsy and is caused by hypocretin deficiency.
  phenotype_term:
    preferred_term: Cataplexy
    term:
      id: HP:0002524
      label: Cataplexy
- name: Sleep Paralysis
  category: Sleep
  frequency: FREQUENT
  notes: Temporary inability to move upon waking or falling asleep
  evidence:
  - reference: PMID:25728441
    supports: SUPPORT
    snippet: "Narcolepsy with cataplexy is caused by hypocretin deficiency owing to destruction of most of the hypocretin-producing neurons in the hypothalamus."
    explanation: Sleep paralysis is part of the narcolepsy symptom tetrad resulting from hypocretin deficiency.
  phenotype_term:
    preferred_term: Sleep Paralysis
    term:
      id: HP:0025233
      label: Sleep paralysis
- name: Hypnagogic Hallucinations
  category: Psychiatric
  frequency: FREQUENT
  notes: Vivid dream-like experiences at sleep onset
  evidence:
  - reference: PMID:25728441
    supports: SUPPORT
    snippet: "Narcolepsy with cataplexy is caused by hypocretin deficiency"
    explanation: Hypnagogic hallucinations are part of the classic narcolepsy tetrad resulting from REM sleep intrusion.
  phenotype_term:
    preferred_term: Hypnagogic Hallucination
    term:
      id: HP:0002519
      label: Hypnagogic hallucination
- name: Disrupted Nighttime Sleep
  category: Sleep
  frequency: FREQUENT
  notes: Fragmented nocturnal sleep despite daytime sleepiness
  evidence:
  - reference: PMID:25728441
    supports: SUPPORT
    snippet: "Narcolepsy with cataplexy is caused by hypocretin deficiency owing to destruction of most of the hypocretin-producing neurons in the hypothalamus."
    explanation: Fragmented nighttime sleep results from impaired sleep-wake regulation due to orexin neuron loss.
  phenotype_term:
    preferred_term: Sleep Disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
biochemical:
- name: CSF Orexin/Hypocretin-1
  presence: Decreased
  context: Low or undetectable in Type 1 narcolepsy (<110 pg/mL)
genetic:
- name: HLA-DQB1*06:02
  association: Risk Factor
  notes: Present in >98% of Type 1 narcolepsy, but also 25% of general population
  evidence:
  - reference: PMID:32227223
    supports: SUPPORT
    snippet: "Autoreactive T cells and autoantibodies have been detected in blood samples from patients"
    explanation: Detection of autoreactive T cells in narcolepsy patients supports the HLA-mediated autoimmune mechanism.
- name: HCRT
  association: Causative
  notes: Rare mutations in hypocretin gene cause familial narcolepsy
  evidence:
  - reference: PMID:25728441
    supports: SUPPORT
    snippet: "Ablation of hypocretin or hypocretin receptors also leads to narcolepsy phenotypes in animal models."
    explanation: Demonstrates that loss of hypocretin gene function causes narcolepsy.
- name: HCRTR2
  association: Causative
  notes: Hypocretin receptor 2 mutations (canine model)
  evidence:
  - reference: PMID:25728441
    supports: SUPPORT
    snippet: "Ablation of hypocretin or hypocretin receptors also leads to narcolepsy phenotypes in animal models."
    explanation: Confirms that hypocretin receptor mutations cause narcolepsy in animal models.
environmental:
- name: H1N1 Infection
  notes: Increased risk after 2009 pandemic
- name: Pandemrix Vaccine
  notes: Associated with increased narcolepsy risk in Europe
- name: Streptococcal Infection
  notes: Possible trigger in some cases
treatments:
- name: Sodium Oxybate
  description: First-line for cataplexy and daytime sleepiness, improves nighttime sleep.
  evidence:
  - reference: PMID:22893778
    supports: SUPPORT
    snippet: "Narcolepsy patients on SXB have significant reductions in cataplexy and daytime sleepiness. SXB is well tolerated in patients with narcolepsy, and most adverse events were mild to moderate in severity."
    explanation: Systematic review and meta-analysis of 6 RCTs confirms efficacy for both cataplexy and sleepiness with acceptable safety.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Modafinil
  description: Wake-promoting agent for excessive daytime sleepiness.
  evidence:
  - reference: PMID:20671626
    supports: SUPPORT
    snippet: "In narcoleptic patients, modafinil in comparison with placebo is effective in the treatment of excessive daytime sleepiness, but not cataplexy."
    explanation: Systematic review and meta-analysis of 9 RCTs confirms modafinil efficacy for excessive daytime sleepiness.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Pitolisant
  description: Histamine H3 receptor antagonist, promotes wakefulness.
  evidence:
  - reference: PMID:34935103
    supports: SUPPORT
    snippet: "The results of this analysis demonstrate the robust efficacy of pitolisant for the reduction in both excessive daytime sleepiness and cataplexy."
    explanation: Analysis of randomized placebo-controlled trials demonstrates large effect sizes for pitolisant.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Solriamfetol
  description: Dopamine/norepinephrine reuptake inhibitor for sleepiness.
  evidence:
  - reference: PMID:30694576
    supports: SUPPORT
    snippet: "Solriamfetol has the potential to be an important therapeutic option for the treatment of impaired wakefulness and excessive sleepiness in patients with narcolepsy."
    explanation: Phase 3 RCT demonstrated significant improvements in MWT and ESS scores versus placebo.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Amphetamines
  description: Traditional stimulants (amphetamine, methylphenidate).
  evidence:
  - reference: PMID:18830438
    supports: SUPPORT
    snippet: "Modafinil has replaced methylphenidate and amphetamine as the first-line treatment of excessive daytime sleepiness (EDS) and sleep attacks"
    explanation: Confirms amphetamines were traditional first-line treatments for EDS before modafinil.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Antidepressants
  description: SNRIs/SSRIs for cataplexy (venlafaxine, fluoxetine).
  evidence:
  - reference: PMID:30837110
    supports: SUPPORT
    snippet: "Venlafaxine demonstrated significantly greater improvements in MSL in the MWT (p < 0.01)."
    explanation: Prospective study of 148 patients showed significant improvement in cataplexy and sleepiness with antidepressants.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Scheduled Naps
  description: Short planned naps can improve alertness.
  evidence:
  - reference: PMID:18830438
    supports: SUPPORT
    snippet: "Non-pharmacologic management of narcolepsy includes scheduled daytime naps to help control excessive sleepiness and improve daytime alertness."
    explanation: This management review describes scheduled daytime naps as an important non-pharmacologic strategy to reduce excessive daytime sleepiness in narcolepsy.
  treatment_term:
    preferred_term: behavioral counseling
    term:
      id: MAXO:0000077
      label: behavioral counseling
datasets:
